Navigation Links
Variation in HIV's ability to disable host defenses contributes to rapid evolution

One of the reasons HIV is so difficult to contain and treat is its rapid evolution. Understanding how host defenses and viral countermeasures contribute to that evolution is vital.

Host cells produce two proteins that mutate HIV DNA and interfere with the virus's ability to replicate. But HIV produces a protein, called Vif, that can disable the two defensive proteins.

Vif is full of variation, both in sequence and in function, according to a new study in PLoS Pathogens, and this could in turn potentially accelerate the evolution of HIV.

Within a single patient, some versions of Vif don't work at all; others counteract only one of the host's defensive proteins. "It's a leaky system," according to Paul D. Bieniasz, senior author of the study and associate professor at The Rockefeller University's Aaron Diamond AIDS Research Center.

Some variations in Vif only partially inactivate the defensive proteins that cause HIV to mutate, and might even promote further variation in the virus within patients. "This work elucidates new pathways which shape the evolution of the virus," says Viviana Simon, lead author of the study.

###

Citation: Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif function can differentially impact APOBEC3G/3F neutralization: A potential role in HIV-1 diversification. PLoS Pathogens 1(1): e6


'"/>

Source:PLoS


Page: 1

Related biology news :

1. Genetic Variation Visualization - From EMBL
2. Variation in womens X chromosomes may explain differences among individuals, between sexes
3. Variation in bitter-taste receptor gene increases risk for alcoholism
4. Variations in detoxifying genes linked to Lou Gehrigs disease
5. “Nano-scissors?laser shows precise surgical capability
6. Enzyme shown to help protect genomic stability
7. Low level of extinction during ice age linked to adaptability
8. Two chemicals boost immune cells ability to fight HIV without gene therapy
9. Molecular messengers perform a crucial role in the ability of injured nerve cells to heal themselves
10. Study shows humans have ability to track odors, much like bloodhounds
11. Locusts built-in surface analysis ability directs them to fly overland
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
Breaking Biology Technology: